Back to results
US 9,517,234 B2Granted
Tetrandrine family pharmaceutical formulations and method
AssigneeCBA Pharma, Inc.
InventorRon D. Carroll
Life of this patent
Estimating the term…
Abstract
Drug formulations, methods and their use in treatment of diseases using formulations of pure di-acid salts of tetrandrine family members, especially d-tetrandrine di-hydrochloride, combined with a pharmaceutical diluent or carrier.
Claims3
A pharmaceutical formulation comprising:
- the pure di-acid salt of d-tetrandrine combined with a pregelatinized starch carrier, colloidal silicone dioxide, sodium lauryl sulfate and magnesium stearate in the following amounts:
- 50 mg d-tetrandrine di-acid salt,
- 384 mg Pregelatinized Starch NF (Starch 1500),
- 4.4 mg Colloidal Silicon Dioxide (Cab-O-Sil M5),
- 0.4 mg Sodium Lauryl Sulfate NF, and
- 1 mg Magnesium Stearate NF.
3 more elements
A pharmaceutical formulation comprising:
- the pure di-acid salt of d-tetrandrine combined with a pregelatinized starch carrier, colloidal silicone dioxide, sodium lauryl sulfate and magnesium stearate in the following amounts:
- 200 mg d-tetrandrine di-acid salt,
- 25.2 mg Pregelatinized Starch 1500 NF,
- 1.5 mg Silicon Dioxide USP,
- 0.25 mg Sodium Lauryl Sulfate NF, and
- 1.25 mg Magnesium Stearate USP.
3 more elements
A pharmaceutical formulation comprising:
- the pure di-acid salt of d-tetrandrine combined with a pregelatinized starch carrier, microcrystalline cellulose, sodium lauryl sulfate and magnesium stearate in the following amounts:
- 100 mg d-tetrandrine di-acid salt,
- 70 mg microcrystalline cellulose,
- 0.2 mg sodium lauryl sulfate, and
- 0.6 mg magnesium stearate.
2 more elements
Dependencies are inferred from the claim text.